Design Therapeutics Inc
DSGN6.250USD
+0.300+5.04%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
355.93MValor de mercado
PerdaP/L TTM
Mais detalhes de Design Therapeutics Inc Empresa
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Informações da empresa
Código da empresaDSGN
Nome da EmpresaDesign Therapeutics Inc
Data de listagemMar 26, 2021
CEODr. Pratik Shah, Ph.D.
Número de funcionários54
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 26
Endereço6005 Hidden Valley Road
CidadeCARLSBAD
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92011
Telefone18582934900
Sitehttps://www.designtx.com/
Código da empresaDSGN
Data de listagemMar 26, 2021
CEODr. Pratik Shah, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Rodney W. Lappe, Ph.D.
Dr. Rodney W. Lappe, Ph.D.
Independent Director
Independent Director
133.02K
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
129.92K
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
57.64K
--
Ms. Deepa Prasad
Ms. Deepa Prasad
Independent Director
Independent Director
20.00K
--
Dr. Heather A Berger ,Ph.D.
Dr. Heather A Berger ,Ph.D.
Independent Director
Independent Director
1.30K
--
Mr. Justin Gover
Mr. Justin Gover
Director
Director
--
--
Dr. Sean Jeffries, Ph.D.
Dr. Sean Jeffries, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Christopher M. (Chris) Storgard, M.D.
Dr. Christopher M. (Chris) Storgard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Lead Independent Director
Lead Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Rodney W. Lappe, Ph.D.
Dr. Rodney W. Lappe, Ph.D.
Independent Director
Independent Director
133.02K
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
129.92K
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
57.64K
--
Ms. Deepa Prasad
Ms. Deepa Prasad
Independent Director
Independent Director
20.00K
--
Dr. Heather A Berger ,Ph.D.
Dr. Heather A Berger ,Ph.D.
Independent Director
Independent Director
1.30K
--
Mr. Justin Gover
Mr. Justin Gover
Director
Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Ansari (Aseem Z. Ph.D.)
13.47%
SR One Capital Management, LP
11.46%
Logos Global Management LP
7.41%
Quan Venture Fund II LP
7.02%
Light Irrevocable Trust.
6.73%
Outro
53.92%
Investidores
Investidores
Proporção
Ansari (Aseem Z. Ph.D.)
13.47%
SR One Capital Management, LP
11.46%
Logos Global Management LP
7.41%
Quan Venture Fund II LP
7.02%
Light Irrevocable Trust.
6.73%
Outro
53.92%
Tipos de investidores
Investidores
Proporção
Corporation
20.48%
Venture Capital
18.87%
Hedge Fund
17.65%
Individual Investor
15.49%
Investment Advisor
13.73%
Investment Advisor/Hedge Fund
8.83%
Private Equity
3.43%
Research Firm
0.37%
Pension Fund
0.09%
Outro
1.05%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
236
55.16M
97.16%
-18.49M
2025Q1
248
55.19M
97.22%
-19.02M
2024Q4
263
54.33M
95.95%
-18.64M
2024Q3
271
52.86M
93.39%
-18.89M
2024Q2
270
52.91M
93.60%
-20.44M
2024Q1
269
51.55M
91.19%
-22.56M
2023Q4
256
52.68M
94.11%
-19.20M
2023Q3
248
54.08M
96.62%
-10.45M
2023Q2
240
59.86M
106.99%
-4.32M
2023Q1
237
59.61M
106.56%
-4.74M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Ansari (Aseem Z. Ph.D.)
7.67M
13.51%
--
--
Mar 31, 2025
SR One Capital Management, LP
6.53M
11.5%
--
--
Mar 31, 2025
Logos Global Management LP
4.22M
7.43%
--
--
Mar 31, 2025
Quan Venture Fund II LP
4.00M
7.04%
-133.00K
-3.22%
Mar 31, 2025
Light Irrevocable Trust.
3.83M
6.75%
--
--
Mar 31, 2025
Star Irrevocable Trust.
3.83M
6.75%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
1.82M
3.2%
-38.89K
-2.09%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.20M
3.88%
-73.03K
-3.21%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.95M
3.44%
--
--
Mar 31, 2025
Tang Capital Management, LLC
1.68M
2.96%
+200.00K
+13.50%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
